MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
MoonLake Immunotherapeutics reported positive topline results from the Phase 3 IZAR-1 trial of sonelokimab in psoriatic arthritis, meeting all primary and key secondary endpoints at Week 16. The trial demonstrated a 42.1% ACR50 response rate with strong efficacy across multiple domains, including 66.5% ACR20 and 61% PASI90 in skin involvement.
Key figures
- Drug Name
- Sonelokimab
- Phase Of Trial
- Phase 3
- Mda
- 41.2%
- Acr20
- 66.5%
- Acr50
- 42.1%
- Pasi90
- 61%
- Net loss
- $61.8 million
- Cash runway
- mid-2028
- Rd expenses
- $50.2 million
- Cash position
- $537.0 million
- Haq di change
- -0.427
- Sf 36 pcs score
- 6.54
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.